A revolutionary new therapy is rapidly emerging for the treatment of some forms of cancer. CAR-T cell therapies genetically engineer a patient’s own immune cells to treat cancer with results that have captured the attention of researchers and the public alike. In 2017, CAR-T cell therapy was the first gene therapy treatment approved in the United States by the Food and Drug Administration (FDA).
Join Dr. Saar Gill, member of a team that pioneered this experimental treatment at the University of Pennsylvania alongside The Franklin Institute’s Chief Bioscientist Dr. Jayatri Das, to delve into an exploration of CAR-T cell therapy—the science behind it, its risks and benefits, plus its potential for treating other forms of cancer.
This event is free, and advanced registration is required. Details here: bit.ly/2KupaTS
This event is part of The Franklin Institute Speaker Series. bit.ly/1QSp20F